Plain-English translation of NCT05975749 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a study for people with gastric (stomach) cancer who have had surgery and are at risk of their cancer returning. The trial is testing whether adding a new immunotherapy drug called , combined with Trastuzumab (a medicine that targets gastric cancer cells) and , works better than alone at keeping the cancer from coming back.
Gastric cancer is serious, and many patients have a cancer recurrence even after surgery. Researchers want to see if this medication can boost the body's own immune system to fight any remaining cancer cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication combination or alone after your surgery. You will likely visit the clinic regularly to receive treatment, have blood tests to monitor your health, and be followed over time to see whether your cancer returns. The study involves 114 patients total and is currently recruiting participants.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~114 participants
Started
January 2023
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 80 Years
Last updated on clinicaltrials.gov in March 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.